| 1359 |
National Cancer Institute |
Html |
en |
Cancer Pain (PDQ®)–Health Professional Version |
Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed. |
| initial pain assessment | 0.567168 |
| baseline pain intensity | 0.558291 |
| treats mild pain | 0.559952 |
| moderate cancer pain | 0.617809 |
| metastatic bone pain | 0.57198 |
| incident cancer pain | 0.559612 |
| acute pain resolves | 0.55829 |
| pain management treatment | 0.568663 |
| ongoing pain management | 0.552517 |
| pain relief ladder | 0.55951 |
| common cancer pain | 0.591113 |
| Neuropathic Pain sections | 0.560808 |
| somatic pain | 0.561569 |
| indicates mild pain | 0.560721 |
| cancer patients | 0.628525 |
| pain intensity | 0.56637 |
| pain management | 0.652391 |
| neuropathic pain | 0.592568 |
| Pain Symptom Manage | 0.699092 |
| cancer pain control | 0.556765 |
| Pain Management Nursing | 0.556277 |
| Pain Physician | 0.561182 |
| pain assessment | 0.597079 |
| Pain Palliat Care | 0.567356 |
| breakthrough cancer pain | 0.563775 |
|
| visceral pain signals | 0.562249 |
| severe cancer pain | 0.582593 |
| PUBMED Abstract | 0.564761 |
| visceral pain | 0.565502 |
| pain assessment toolkit | 0.554382 |
| mild pain | 0.57672 |
| Effective pain management | 0.567467 |
| cancer pain management | 0.592002 |
| pain relief | 0.569023 |
| moderate pain | 0.568137 |
| cancer pain | 0.834476 |
| American Pain Society | 0.557173 |
| pain | 0.954306 |
| acute pain | 0.572092 |
| Abstract | 0.595673 |
| Pain Med | 0.572479 |
| Clin Oncol | 0.552396 |
| severe pain | 0.584777 |
| cancer pain experience | 0.579997 |
| pain scale | 0.566028 |
| pain levels | 0.565618 |
| comprehensive pain assessment | 0.576005 |
| indicates moderate pain | 0.564768 |
| pain receptors | 0.555011 |
|
CLICK HERE |
| 1415 |
National Cancer Institute |
Html |
en |
Grief, Bereavement, and Coping With Loss (PDQ®)–Patient Version |
Expert-reviewed report about grief, bereavement, and feelings of loss in survivors of someone who has died of cancer. Grief in children is also discussed. |
| normal grief process | 0.471417 |
| Common grief reactions | 0.532686 |
| grief pattern | 0.454756 |
| bereaved person moves | 0.399208 |
| family member | 0.390974 |
| PDQ cancer information | 0.489866 |
| unexpected loss | 0.387668 |
| loss | 0.666269 |
| children | 0.561087 |
| typical grief response | 0.466341 |
| PDQ Grief | 0.446846 |
| clinical trials | 0.426876 |
| grief | 0.931776 |
| anticipatory grief | 0.60415 |
| cancer information summary | 0.442789 |
| social support | 0.46161 |
| clinical trial | 0.441424 |
| younger bereaved people | 0.426523 |
| family members | 0.386464 |
| Grief bursts | 0.441053 |
| weight loss | 0.372081 |
| bereaved people | 0.499808 |
| severe grief | 0.457196 |
| difficult grief | 0.440844 |
|
| NCI PDQ cancer | 0.383634 |
| grief reactions | 0.581886 |
| person | 0.556278 |
| grief symptoms | 0.442678 |
| deceased person | 0.373691 |
| child | 0.531789 |
| distress | 0.378808 |
| normal grief | 0.541883 |
| death | 0.826955 |
| Chronic grief | 0.43943 |
| Cancer Information Service | 0.369255 |
| complicated grief | 0.451713 |
| National Cancer Institute | 0.448538 |
| health care | 0.379094 |
| grief process | 0.5341 |
| Palliative Care Editorial | 0.392193 |
| new treatment | 0.370063 |
| different cultures | 0.372731 |
| Care Editorial Board | 0.393341 |
| people | 0.580964 |
| way | 0.395094 |
| grief treatment | 0.44457 |
| comprehensive cancer information | 0.368169 |
| depression | 0.378859 |
|
CLICK HERE |
| 1735 |
National Cancer Institute |
Html |
en |
Reproductive History and Cancer Risk |
A fact sheet that describes what is known about the relationship between pregnancy, miscarriage, abortion, fertility treatment and the risk of cancer. |
| spontaneous abortion | 0.436313 |
| additional full-term pregnancy | 0.438399 |
| reproductive factors | 0.477411 |
| British Journal | 0.464068 |
| Breast Cancer Research | 0.554497 |
| Long-term cancer risk | 0.463368 |
| reduced risk | 0.446487 |
| ovarian cancer | 0.487507 |
| Smalley M. Pregnancy | 0.434754 |
| future breast cancer | 0.499324 |
| pregnancy | 0.509986 |
| lower risk | 0.435353 |
| cancer types | 0.43982 |
| receptor-negative breast cancer | 0.516576 |
| maternal breast cancer | 0.498304 |
| slightly higher risk | 0.457714 |
| Cancer Epidemiology | 0.469709 |
| ovarian stimulation | 0.442204 |
| breast cancer declines | 0.516281 |
| endometrial cancer | 0.444521 |
| International Journal | 0.437218 |
| women | 0.502711 |
| risk reduction | 0.435107 |
| ovarian hormones | 0.434429 |
| invasive ovarian cancer | 0.459634 |
|
| breast cells | 0.485604 |
| decreased risk | 0.446489 |
| cancer cells | 0.451518 |
| Breast cancer incidence | 0.495609 |
| full-term pregnancy | 0.496243 |
| Endocrine-Related Cancer | 0.440218 |
| breast tissue | 0.475053 |
| studies | 0.44347 |
| epithelial ovarian cancer | 0.455081 |
| ovarian cancer risk | 0.471705 |
| epidemiological studies | 0.438401 |
| higher risk | 0.46047 |
| endocrine-related risk factors | 0.447705 |
| breast cancer risk | 0.823683 |
| receptor–positive breast cancer | 0.54092 |
| breast cancer | 0.983763 |
| van leeuwen fe | 0.44337 |
| pregnancy-related factors | 0.45934 |
| vitro fertilization | 0.434549 |
| Colditz GA | 0.436762 |
| fertility drugs | 0.477238 |
| receptor–negative breast cancers | 0.493334 |
| et al | 0.597414 |
| Vatten LJ | 0.446247 |
|
CLICK HERE |
| 1865 |
National Cancer Institute |
Html |
es |
Tratamiento de los síndromes mielodisplásicos (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los síndromes mielodisplásicos. |
| int-1-risk mds with | 0.306049 |
| displasia multilinaje | 0.307414 |
| results from | 0.303983 |
| granulocyte colony-stimulating factor | 0.309016 |
| neoplasias mieloides | 0.312984 |
| Garcia-Manero G | 0.313072 |
| único tratamiento | 0.304306 |
| with erythropoietin | 0.312779 |
| anomalÃa citogenética | 0.307792 |
| fase ii | 0.312681 |
| international prognostic scoring | 0.321295 |
| anomalÃas citogenéticas | 0.312714 |
| randomized study | 0.305169 |
| risk factors | 0.304186 |
| stem cell transplantation | 0.306118 |
| displasia unilinaje | 0.30428 |
| PDQ Fatiga | 0.308455 |
| Hypoplastic myelodysplastic | 0.304869 |
| syndromes treated with | 0.307198 |
| MDS with | 0.310074 |
| patients with | 0.448968 |
| with granulocyte colony-stimulating | 0.305945 |
| patients with lower | 0.307744 |
| marrow transplantation | 0.304031 |
| células madre | 0.305457 |
|
| crecimiento mieloide | 0.304117 |
| leucemia aguda | 0.308968 |
| elderly patients with | 0.307457 |
| sÃndromes mielodisplásicos | 0.421016 |
| Anderson Cancer Center | 0.305709 |
| hematopoietic stem-cell transplantation | 0.306245 |
| syndrome results | 0.304563 |
| SMD neutropénicos asintomáticos | 0.311641 |
| PDQ Tratamiento | 0.30516 |
| MD Anderson Cancer | 0.305795 |
| PDQ Neoplasias | 0.304911 |
| Clin Oncol | 0.347749 |
| US patients with | 0.307961 |
| Sekeres MA | 0.309258 |
| Kantarjian H | 0.309886 |
| Conditioning with targeted | 0.305451 |
| Hellström-Lindberg E | 0.307604 |
| prognostic scoring system | 0.330511 |
| leucemia mieloide aguda | 0.3404 |
| treated with | 0.308208 |
| with recombinant | 0.304816 |
| patients with myelodysplastic | 0.404348 |
| from patients with | 0.307143 |
| myelodysplastic syndrome | 0.965311 |
|
CLICK HERE |
| 1870 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de células germinativas del ovario (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del ovario. |
| germ-cell tumors | 0.421459 |
| germ-cell tumors with | 0.411803 |
| Obstet Gynecol | 0.406415 |
| ovarian germ | 0.634072 |
| malignant germ | 0.435096 |
| endodermal sinus tumor | 0.403615 |
| cell tumors treated | 0.404749 |
| Liao SY | 0.410388 |
| Adjuvant therapy | 0.410358 |
| Gershenson DM | 0.467949 |
| Current therapy | 0.403318 |
| Williams SD | 0.494559 |
| tumores malignos mixtos | 0.404882 |
| Hacker NF | 0.402853 |
| Instituto Nacional | 0.403668 |
| high-dose chemotherapy | 0.403104 |
| or etoposide | 0.404727 |
| DiSaia PJ | 0.408704 |
| Moore DH | 0.407371 |
| University Medical Center | 0.403543 |
| quimioterapia postoperatoria | 0.403765 |
| Gynecol Oncol | 0.453558 |
| pacientes jóvenes | 0.408368 |
| lavados peritoneales | 0.410402 |
| New York University | 0.403494 |
|
| Icb Tumor | 0.403092 |
| gynecologic oncology group | 0.703201 |
| Blessing JA | 0.51199 |
| Birch R | 0.404259 |
| estadio iv | 0.424378 |
| Einhorn LH | 0.40484 |
| Dembo AJ | 0.402909 |
| estadio ia | 0.408575 |
| ovary with | 0.410468 |
| Morris M | 0.407706 |
| with advanced germ | 0.403782 |
| IIIa Tumor | 0.403067 |
| York University Medical | 0.403528 |
| Intern Med | 0.411687 |
| second-look laparotomy | 0.431921 |
| Clin Oncol | 0.539728 |
| estadio iii | 0.41476 |
| cell tumors using | 0.405334 |
| tumor macroscópico | 0.402814 |
| Oncology Group Study | 0.403519 |
| germ cell tumors | 0.985883 |
| histerectomÃa abdominal | 0.412918 |
| Cangir A | 0.408111 |
| cell tumors with | 0.436879 |
|
CLICK HERE |
| 3421 |
National Cancer Institute |
Html |
es |
Antioxidantes y prevención del cáncer |
Antioxidants are substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer. Antioxidants interact with and stabilize free radicals and may prevent some of the damage fre |
| nutrition intervention trial | 0.318966 |
| Population Nutrition Intervention | 0.307215 |
| Minerales Antioxidantes | 0.329026 |
| mortality during | 0.312847 |
| skin cancers | 0.309111 |
| Hercberg S | 0.31386 |
| complementos antioxidantes alimenticios | 0.358441 |
| vitamina c | 0.306663 |
| vitamina a | 0.307237 |
| Klein EA | 0.307093 |
| vitamina e | 0.306864 |
| Virtamo J | 0.307865 |
| mortality after | 0.306705 |
| antioxidantes alimenticios | 0.533634 |
| stopping antioxidant vitamins | 0.315828 |
| Internal Medicine | 0.308526 |
| Estados Unidos | 0.333664 |
| antioxidant vitamins | 0.315879 |
| PubMed Abstract | 0.94039 |
| Estudio Demográfico | 0.30775 |
| follow-up after stopping | 0.328778 |
| after stopping antioxidant | 0.315902 |
| skin cancers during | 0.306731 |
| minerales selenio | 0.30885 |
| health beneficial effects | 0.308495 |
|
| randomized controlled | 0.317735 |
| International Journal | 0.310662 |
| health effects | 0.306579 |
| Kristal AR | 0.308705 |
| tomar complementos | 0.660547 |
| Taylor PR | 0.316391 |
| Ezzedine K | 0.307269 |
| general population | 0.307041 |
| supplemental alpha-tocopherol | 0.309241 |
| Kesse-Guyot E | 0.307458 |
| tract cancers | 0.32431 |
| médicos varones | 0.307704 |
| beta carotene | 0.315537 |
| elemento mineral selenio | 0.311109 |
| Cancer Prevention Study | 0.31922 |
| Cancer Prevention Trial | 0.339926 |
| complementos alimenticios | 0.353561 |
| retinol efficacy trial | 0.343648 |
| SU.VI.MAX Study | 0.30914 |
| radicales libres | 0.808852 |
| resultados mixtos | 0.310828 |
| Cancer Institute | 0.352968 |
| New England Journal | 0.317494 |
| Cancer Prevention | 0.362527 |
|
CLICK HERE |
| 3444 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de cavidad oral y orofaringe. |
| Ramadas K | 0.326456 |
| Sankaranarayanan R | 0.337876 |
| accessed march | 0.331249 |
| Zhang L | 0.310727 |
| Clinical Preventive Services | 0.308765 |
| Interim results from | 0.307724 |
| Sin embargo | 0.381657 |
| Kerr AR | 0.312561 |
| American Cancer Society | 0.427439 |
| Early findings from | 0.308051 |
| CA Cancer | 0.323169 |
| cluster randomized controlled | 0.308479 |
| oral pre-malignant | 0.326412 |
| oral cancer | 0.913191 |
| Preventive Services Task | 0.376173 |
| Instituto Nacional | 0.317765 |
| Cancer Res | 0.323621 |
| Human papillomavirus infection | 0.307515 |
| PDQ Exámenes | 0.32226 |
| oral cancer screening | 0.566684 |
| Estados Unidos | 0.310609 |
| Morton TH Jr | 0.307383 |
| Morton TH | 0.311837 |
| Epstein JB | 0.323025 |
| Database Syst Rev | 0.307163 |
|
| visual screening | 0.315772 |
| screening with | 0.315479 |
| upper aerodigestive tract | 0.307566 |
| SEER Cancer Statistics | 0.324889 |
| Cancer Society guidelines | 0.325639 |
| Trivandrum Oral Cancer | 0.343561 |
| carcinoma versus lesiones | 0.311231 |
| Jacob BJ | 0.31089 |
| potentially malignant disorders | 0.308445 |
| Cancer Facts | 0.324242 |
| Long term effect | 0.3078 |
| adjacent to clinically | 0.307949 |
| Oral Oncol | 0.526329 |
| oral verrucous | 0.325426 |
| National Cancer Institute | 0.351683 |
| center grapples with | 0.307601 |
| Oral Pathol Med | 0.361585 |
| Screening Study Group | 0.316915 |
| Am Dent Assoc | 0.308416 |
| Services Task Force | 0.375429 |
| Fluorescence visualization detection | 0.308258 |
| detección versus atención | 0.319469 |
| Brief Evidence Update | 0.307856 |
| Poh CF | 0.312257 |
|
CLICK HERE |
| 3565 |
National Cancer Institute |
Html |
en |
Funding Opportunities |
Find a wide range of funding announcements to support cancer research and training, organized by topic and by funding mechanism. |
| population sciences | 0.493717 |
| promising research areas | 0.56879 |
| research grants | 0.500944 |
| AIDS-related cancer | 0.494918 |
| Cancer Clinical Proteomics | 0.567175 |
| Cancer Complementary | 0.503257 |
| mutant RAS-driven cancers | 0.494379 |
| Cancer Moonshot Blue | 0.59594 |
| Cancer Nanotechnology Research | 0.679363 |
| Cancer program | 0.497422 |
| research community | 0.507936 |
| cancer patients | 0.484719 |
| Research projects | 0.502551 |
| Basic cancer research | 0.680007 |
| Tissue Sample Collection | 0.485994 |
| Reduce Cancer Health | 0.579079 |
| Trans-NIH Research Project | 0.629695 |
| Cancer Health Disparities | 0.713271 |
| surveillance cancer research | 0.666086 |
| basic cancer biology | 0.601818 |
| Cancer Control | 0.538781 |
| biostatistical funding opportunities | 0.51758 |
| Cancer Moonshotâ„ Funding | 0.624526 |
| Ribbon Panel recommendations | 0.479686 |
|
| cancer prevention | 0.563482 |
| Cancer Treatment | 0.485294 |
| epidemiological research | 0.487712 |
| alternative medicine practice | 0.49686 |
| NCI Alliance | 0.464504 |
| Provocative Questions Program | 0.51458 |
| cancer research | 0.973473 |
| treat cancer | 0.476905 |
| recent NCI-supported RFAs | 0.522382 |
| cancer screening procedures | 0.560144 |
| alternative medicine | 0.550525 |
| Analysis Technologies Program | 0.493099 |
| small business | 0.635559 |
| private sector participation | 0.462098 |
| health disparities perspective | 0.521069 |
| RAS Initiative enlists | 0.522897 |
| Outstanding Investigator Award | 0.657445 |
| NCI initiative | 0.486583 |
| Biospecimen Research Branch | 0.595175 |
| Business Innovation Research | 0.566067 |
| Translational Research | 0.497403 |
| Business Technology Transfer | 0.60463 |
| Small Business Technology | 0.604737 |
| research communities | 0.503329 |
|
CLICK HERE |
| 16662 |
National Cancer Institute |
Html |
es |
Qué son el “cerebro en quimio” y el deterioro cognoscitivo después de tratamiento de cáncer |
Actualización acerca de la investigación de los factores que tienen una función en el |
| gen apoe | 0.427379 |
| información meses | 0.42886 |
| ¿estos problemas | 0.43724 |
| doctor ahles | 0.800077 |
| peor desempeño | 0.428323 |
| recientes investigaciones | 0.427457 |
| gemelos idénticos —una | 0.452424 |
| larga duración | 0.464561 |
| cuáles pacientes | 0.458793 |
| edad afÃn | 0.424345 |
| variado deterioro | 0.472498 |
| Wilmot Cancer Institute | 0.444334 |
| Funciones Cognoscitivas | 0.442034 |
| gen bdnf | 0.427202 |
|
| doctor tim ahles | 0.462437 |
| oncológico integral jonsson | 0.458544 |
| llamada evaluación funcional | 0.440824 |
| antidepresivo fluoxetina | 0.426333 |
| sistema nervioso central | 0.4425 |
| doctora rowland | 0.544141 |
| actividad neurotransmisor | 0.425054 |
| doctora patricia ganz | 0.777152 |
| Oncológico Memorial Sloan | 0.455699 |
| doctora julia rowland | 0.500519 |
| quimioterapia 5-FU | 0.47139 |
| doctora michelle janelsins | 0.489763 |
| gen comt | 0.425879 |
|
CLICK HERE |
| 17188 |
National Cancer Institute |
Html |
en |
Fertility Issues in Boys and Men with Cancer |
Fertility issues are common in boys and men getting cancer treatment. Fertility preservation options include sperm banking, testicular shielding, testicular sperm extraction (TESE), and testicular tissue freezing. Support and clinical trials are listed. |
| Sexual Health Issues | 0.508548 |
| cancer treatment | 0.619036 |
| fertility | 0.97146 |
| baseline fertility | 0.628851 |
| family member | 0.464194 |
| cancer therapy | 0.481706 |
| health care team | 0.501109 |
| sperm counts | 0.505642 |
| fertility problems | 0.606189 |
| stem cell transplants | 0.576694 |
| upsetting long-term effects | 0.50079 |
| Sperm banking | 0.500128 |
| Testicular tissue freezing | 0.505046 |
| specific treatment | 0.473076 |
| fertility clinic | 0.610475 |
| professionally led support | 0.49722 |
| sperm-forming cells | 0.50982 |
| reproductive endocrinologist | 0.471953 |
| fertility options | 0.634938 |
| fertility preservation procedures | 0.624595 |
| Testicular sperm extraction | 0.553558 |
| radiation therapy | 0.551741 |
| testicular shielding | 0.519544 |
| sperm cells | 0.508932 |
| Reproductive Medicine | 0.463459 |
|
| cancer treatments | 0.62693 |
| blood stem cell | 0.500463 |
| personal health factors | 0.507399 |
| fertility preservation options | 0.794614 |
| testicular tissue cryopreservation | 0.506676 |
| scatter radiation | 0.468354 |
| male cancer patients | 0.603613 |
| fertility preservation | 0.823931 |
| young male cancer | 0.600402 |
| fertility risks | 0.574477 |
| LIVESTRONG Fertility | 0.586472 |
| rectal cancer | 0.479468 |
| reproductive age | 0.463816 |
| sperm | 0.578609 |
| infertility | 0.495824 |
| doctor | 0.471639 |
| fertility specialist | 0.642942 |
| reproductive medical information | 0.506006 |
| cancer | 0.662671 |
| fertility preservation clinic | 0.634592 |
| fertility preservation discounts | 0.62021 |
| bone marrow transplants | 0.501862 |
| child’s doctor | 0.462088 |
| reproductive organs | 0.558126 |
|
CLICK HERE |